CoChat
Sign Up
Cited by 111Diabetes Treatment and ManagementPancreatic function and diabetesDiabetes Management and Research

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Differential Effects of Acute and Extended Infusions of Glucagon-Like Peptide-1 on First- and Second-Phase Insulin Secretion in Diabetic and Nondiabetic Humans

Open access
Quddusi, Shaista, Vahl, Torsten P., Hanson, Kevin, Prigeon, Ronald L., D’Alessio, David A.·2003·Diabetes Care
DOI 10.2337/diacare.26.3.791
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE—The purpose of this study was to determine whether an extended infusion of the incretin hormone glucagon-like peptide 1 (GLP-1) has a greater effect to promote insulin secretion in type 2 diabetic subjects than acute administration of the peptide. RESEARCH DESIGN AND METHODS—Nine diabetic subjects and nine nondiabetic volunteers of similar age and weight were studied in identical protocols. First-phase insulin release (FPIR; the incremental insulin response in the first 10 min after the intravenous glucose bolus) and second-phase insulin release (SPIR; the incremental insulin response from 10–60 min after intravenous glucose) were measured during three separate intravenous glucose tolerance tests (IVGTTs): 1) without GLP-1 (control); 2) with acute administration of GLP-1 as a square wave starting just before glucose administration; and 3) with an extended infusion of GLP-1 for 3 h before and during the IVGTT. RESULTS—In the subjects with diabetes, FPIR was severely impaired—a defect that was only modestly improved by acute administration of GLP-1 (197 ± 97 vs. 539 ± 218 pmol/l · min, P < 0.05), while SPIR was substantially increased (1,952 ± 512 vs. 8,072 ± 1,664 pmol/l · min, P < 0.05). In contrast, the 3-h preinfusion of GLP-1 normalized fasting hyperglycemia (7.9 ± 0.5 vs. 5.2 ± 0.6, P < 0.05), increased FPIR by 5- to 6-fold (197 ± 97 vs. 1,141 ± 409 pmol/l · min, P < 0.05), and augmented SPIR significantly (1,952 ± 512 vs. 4,026 ± 851 pmol/l · min, P < 0.05), but to a lesser degree than the acute administration of GLP-1. In addition, only the 3-h GLP-1 preinfusion significantly improved intravenous glucose tolerance (Kg control 0.61 ± 0.04, acute infusion 0.71 ± 0.04, P = NS; 3-h infusion 0.92 ± 0.08%/min, P < 0.05). These findings were also noted in the nondiabetic subjects in whom acute administration of GLP-1 significantly increased SPIR relative to the control IVGTT (9,439 ± 2,885 vs. 31,553 ± 11660 pmol/l · min, P < 0.001) with less effect on FPIR (3,221 ± 918 vs. 4,917 ± 1,614 pmol/l · min, P = 0.075), while the 3-h preinfusion of GLP-1 significantly increased both FPIR (3,221 ± 918 vs. 7,948 ± 2,647 pmol/l · min, P < 0.01) and SPIR (9,439 ± 2,885 vs. 21,997 ± 9,849 pmol/l · min, P < 0.03). CONCLUSIONS—Extended administration of GLP-1 not only augments glucose-stimulated insulin secretion, but also shifts the dynamics of the insulin response to earlier release in both diabetic and nondiabetic humans. The restitution of some FPIR in subjects with type 2 diabetes is associated with significantly improved glucose tolerance. These findings demonstrate the benefits of a 3-h infusion of GLP-1 on β-cell function beyond those of an acute insulin secretagogue, and support the development of strategies using continuous or prolonged GLP-1 receptor agonism for treating diabetic patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.26.3.791

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Quddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A.
Affiliations
  • University of Washington (US)
  • University of Cincinnati (US)
  • University of Maryland, Baltimore (US)
ORCID
Venue
Diabetes Care
Publisher
American Diabetes Association
Published
2003-03-01
Volume
26
Issue
3
Pages
791-798
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
DOI
10.2337/diacare.26.3.791
OpenAlex
W2043869817
Cited by
111
References
40
Citations by year
2026: 1 · 2023: 1 · 2021: 4 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 10 · 2015: 5 · 2014: 7 · 2013: 12 · 2012: 3
FWCI
4.11
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • U.S. Department of Veterans Affairs
  • University of Washington
  • National Institutes of Health (5r01dk034397-12, RR08084)
  • Geriatric Research Education and Clinical Center
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 54263, DK-34397)
  • National Center for Research Resources (M01RR008084, RR00037, RR08084)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, insulin secretion, first-phase insulin release, second-phase insulin release, type 2 diabetes, incretins, prolonged infusion, acute drug administration, glucose tolerance, fasting hyperglycemia, beta-cell function, intravenous glucose tolerance test, insulin resistance, glucose-stimulated insulin secretion
MeSH terms
Insulin Secretion, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucagon, Humans, Infusions, Intravenous, Insulin, Islets of Langerhans, Male, Middle Aged, Peptide Fragments, Protein Precursors, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review